TME Pharma's proprietary technology generates compounds we refer to as Spiegelmers*, which are a new class of therapeutics designed to combine the benefits of small chemical molecules and biologicals.
Spiegelemers offer a set of significant advantages over existing drug classes:
- High affinity and specificity for targets with demonstrated sustained activity on chemokines in clinical trials
- Can be manufactured chemically and do not require complex biological production processes
- High bio-stability and immunologically passive
- Good safety and tolerability profile based on results from more than 10 trials in over 300 human subjects
Spiegelmers use Mirror-image (L-stereoisomer) chemistry to build injectable oligonucleotide (RNA or DNA) therapeutics that directly bind and neutralize protein targets in the extracellular space.
TME Pharma has established optimized production and quality control methods in-house and with partners for production in accordance with good manufacturing practices (GMP).